Growth Stimulation of Tumor-specific Cytotoxic T Lymphocytes on Concanavalin A-immobilized Carrier Beads

Overview

Journal Cytotechnology

Specialties Biotechnology
Genetics

Date 2012 Feb 24

PMID 22359002

Citations 2

Authors

S Q Liu

L S Liu

T Ohno

Affiliations

Soon will be listed here.

Abstract

Human tumor-specific CD4(+) cytotoxic T lymphocytes (CTL) were generated against duodenum papilloma cell line TGBC18TKB from HLA type-matched peripheral blood mononuclear cells. Concanavalin A (Con A) immobilized on carrier beads stimulated growth of the CTL in a long-term culture without repeated antigen stimulation, while soluble Con A induced death of the CTL. The CTL exhibited the target-specific cytotoxicity in a more potent manner than those before the long-term culture in the presence of the immobilized Con A. Enhanced expression of the adhesion molecule, CD11b, was observed on the CTL. These results suggest that immobilized Con A will be useful for continuous growth stimulation and large scale expansion of CTL without tumor antigen.

Citing Articles

Establishment and characterization of DPC-X4: a novel mixed-type ampullary cancer cell line.

Chai C, Tang H, Yi J, Li L, Yu C, Su Y Hum Cell. 2024; 37(2):531-545.

PMID: 38253956 DOI: 10.1007/s13577-023-01023-0.

Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1.

Xu H, Chai C, Miao X, Tang H, Hu J, Zhang H World J Gastroenterol. 2023; 29(17):2642-2656.

PMID: 37213400 PMC: 10198051. DOI: 10.3748/wjg.v29.i17.2642.

References

Reeke Jr G, BECKER J, Cunningham B, Gunther G, Wang J, Edelman G . Relationships between the structure and activities of concanavalin A. Ann N Y Acad Sci. 1974; 234(0):369-82. DOI: 10.1111/j.1749-6632.1974.tb53049.x. View

YAHARA I, Edelman G . Restriction of the mobility of lymphocyte immunoglobulin receptors by concanavalin A. Proc Natl Acad Sci U S A. 1972; 69(3):608-12. PMC: 426517. DOI: 10.1073/pnas.69.3.608. View

Norris D . Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol. 1990; 95(6 Suppl):111S-120S. DOI: 10.1111/1523-1747.ep12874977. View

Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T . Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer. 1991; 68(11):2391-6. DOI: 10.1002/1097-0142(19911201)68:11<2391::aid-cncr2820681110>3.0.co;2-7. View

Fisk B, Blevins T, Wharton J, Ioannides C . Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995; 181(6):2109-17. PMC: 2192068. DOI: 10.1084/jem.181.6.2109. View

Crowley N, Darrow T, Quinn-Allen M, Seigler H . MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol. 1991; 146(5):1692-9. View

Powell A, Leon M . Reversible interaction of human lymphocytes with the mitogen concanavalin A. Exp Cell Res. 1970; 62(2):315-25. DOI: 10.1016/0014-4827(70)90560-4. View

Liu S, Ito Y, Imanishi Y . Cell growth on immobilized cell-growth factor; 4: Interaction of fibroblast cells with insulin immobilized on poly(methyl methacrylate) membrane. J Biochem Biophys Methods. 1992; 25(2-3):139-48. DOI: 10.1016/0165-022x(92)90006-v. View

Liu S, Saijo K, Todoroki T, Ohno T . Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med. 1995; 1(3):267-71. DOI: 10.1038/nm0395-267. View

10.

Lau L, Jamieson B, Somasundaram T, Ahmed R . Pillars Article: Cytotoxic T-cell Memory without Antigen. Nature. 1994. 369: 648-652. J Immunol. 2013; 190(9):4445-9. View

11.

Goedegebuure P, Douville L, Li H, Richmond G, Schoof D, Scavone M . Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol. 1995; 13(8):1939-49. DOI: 10.1200/JCO.1995.13.8.1939. View

12.

Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K . Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994; 24(3):759-64. DOI: 10.1002/eji.1830240340. View

13.

Shinohara N, Bluestone J, Sachs D . Cloned cytotoxic T lymphocytes that recognize an I-A region product in the context of a class I antigen. J Exp Med. 1986; 163(4):972-80. PMC: 2188072. DOI: 10.1084/jem.163.4.972. View

14.

Groux H, Monte D, Plouvier B, Capron A, Ameisen J . CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-gamma and accessory cells. Eur J Immunol. 1993; 23(7):1623-9. DOI: 10.1002/eji.1830230734. View

15.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E . Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994; 91(14):6458-62. PMC: 44221. DOI: 10.1073/pnas.91.14.6458. View

16.

van Noesel C, Miedema F, Brouwer M, de Rie M, Aarden L, van Lier R . Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature. 1988; 333(6176):850-2. DOI: 10.1038/333850a0. View

17.

Kawakami Y, Eliyahu S, Sakaguchi K, Robbins P, Rivoltini L, Yannelli J . Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180(1):347-52. PMC: 2191573. DOI: 10.1084/jem.180.1.347. View

18.

Bakker A, Schreurs M, Tafazzul G, de Boer A, Kawakami Y, Adema G . Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer. 1995; 62(1):97-102. DOI: 10.1002/ijc.2910620118. View

19.

Kawai K, Sasaki T, Saijo-Kurita K, Akaza H, Koiso K, Ohno T . Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay. Cancer Immunol Immunother. 1992; 35(4):225-9. PMC: 11038884. DOI: 10.1007/BF01789327. View

20.

Freedman R, Tomasovic B, Templin S, Atkinson E, Kudelka A, Edwards C . Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods. 1994; 167(1-2):145-60. DOI: 10.1016/0022-1759(94)90084-1. View